Radiomics analysis based on dynamic contrast-enhanced MRI for predicting early recurrence after hepatectomy in hepatocellular carcinoma patients.
Authors
Affiliations (3)
Affiliations (3)
- General Surgery, Cancer Center, Department of Hepatobiliary and Pancreatic Surgery and Minimal Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang Province, China.
- Department of the Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China.
- General Surgery, Cancer Center, Department of Hepatobiliary and Pancreatic Surgery and Minimal Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang Province, China. [email protected].
Abstract
This study aimed to develop a machine learning model based on Magnetic Resonance Imaging (MRI) radiomics for predicting early recurrence after curative surgery in patients with hepatocellular carcinoma (HCC).A retrospective analysis was conducted on 200 patients with HCC who underwent curative hepatectomy. Patients were randomly allocated to training (n = 140) and validation (n = 60) cohorts. Preoperative arterial, portal venous, and delayed phase images were acquired. Tumor regions of interest (ROIs) were manually delineated, with an additional ROI obtained by expanding the tumor boundary by 5 mm. Radiomic features were extracted and selected using the Least Absolute Shrinkage and Selection Operator (LASSO). Multiple machine learning algorithms were employed to develop predictive models. Model performance was evaluated using receiver operating characteristic (ROC) curves, decision curve analysis, and calibration curves. The 20 most discriminative radiomic features were integrated with tumor size and satellite nodules for model development. In the validation cohort, the clinical-peritumoral radiomics model demonstrated superior predictive accuracy (AUC = 0.85, 95% CI: 0.74-0.95) compared to the clinical-intratumoral radiomics model (AUC = 0.82, 95% CI: 0.68-0.93) and the radiomics-only model (AUC = 0.82, 95% CI: 0.69-0.93). Furthermore, calibration curves and decision curve analyses indicated superior calibration ability and clinical benefit. The MRI-based peritumoral radiomics model demonstrates significant potential for predicting early recurrence of HCC.